Loop diuretic for volume-mediated hypertension in CKD stage 4

HTNmedium

A 68-year-old man with hypertension, diabetes, and CKD stage 4 reports increasing pedal edema and rising home BP readings averaging 150/80 mm Hg. He adheres to a diet of <2 g sodium daily. Medications are losartan, dapagliflozin, and insulin. Office BP is 155/65 mm Hg. Lungs are clear, and he has 1+ bilateral lower-extremity edema to the shins. Potassium is 4.9 mEq/L and creatinine 2.8 mg/dL. What is the most appropriate next step?

  1. A.Prescribe furosemideCorrect
  2. B.Decrease sodium intake to 1 g daily
  3. C.Prescribe amlodipine
  4. D.Obtain 24-hour ambulatory BP monitoring

Explanation

The most appropriate next step is to prescribe furosemide. This patient with CKD stage 4 has new pedal edema and rising home and office BP despite reported dietary sodium restriction, losartan, and dapagliflozin. As GFR falls, the kidney's capacity to excrete sodium declines, and extracellular volume expansion becomes the dominant driver of hypertension. Treating the volume excess is therefore the most effective way to lower BP and relieve edema. Loop diuretics remain effective at low GFR, unlike conventional thiazides, which lose much of their natriuretic effect below an eGFR of about 30 mL/min/1.73 m². Because loop diuretics must be secreted into the tubular lumen, higher doses are needed in advanced CKD, and twice-daily dosing limits post-diuretic sodium retention. KDIGO 2021 recommends a systolic BP target below 120 mm Hg when tolerated, measured with standardized technique, and his BP is well above that. A loop diuretic also counteracts the potassium of 4.9 mEq/L, which would otherwise limit RAS blockade. Chlorthalidone, as in CLICK, is an alternative in stage 4 CKD, but loop diuretics are first-line when edema is present. Ambulatory BP monitoring is valuable to identify white-coat or masked hypertension, but home and office readings agree, and the edema confirms volume expansion. Monitoring would delay needed treatment without changing it. Amlodipine lowers BP but causes dose-dependent peripheral edema through precapillary vasodilation, and it does not address the underlying sodium and volume excess. It could be added later if BP remains elevated after euvolemia is achieved. Further restriction of sodium intake to 1 g daily is impractical and difficult to sustain, risks inadequate nutrition in a patient with advanced CKD, and is unlikely to correct established volume expansion alone. The patient already reports a sodium intake below 2 g daily, the level recommended by KDIGO.

Why each option

A.
Correct. Volume expansion drives hypertension in stage 4 CKD, and loop diuretics remain natriuretic at low eGFR while also offsetting the potassium of 4.9 mEq/L.
B.
He already reports sodium intake below 2 g daily; a 1-g restriction is impractical, risks malnutrition, and will not reverse established volume expansion.
C.
Amlodipine lowers BP but worsens peripheral edema and does not correct the sodium and volume excess driving hypertension in stage 4 CKD.
D.
Home and office readings agree and edema confirms volume expansion, so ambulatory monitoring would delay treatment without changing management.

Reference: KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD; Agarwal R, N Engl J Med 2021 (CLICK)

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

More HTN questions

Browse other topics